ClinicalTrials.gg
Enrolling by invitationNCT07850843APREM-CUUpdated Sep 30, 2026

Apremilast Added to Antihistamines in Chronic Urticaria

A Phase 2 interventional study of Apremilast and Second-generation H1 antihistamine in Chronic Urticaria, Chronic Spontaneous Urticaria and Chronic Inducible Urticaria, sponsored by Rashid Latif Medical College. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Rashid Latif Medical College · Phase 2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study evaluates whether adding oral apremilast, a phosphodiesterase-4 inhibitor, to second-generation H1 antihistamines improves disease activity and quality of life in adults with chronic urticaria that is not controlled by antihistamines alone. Patients who chose apremilast plus antihistamines were compared over 12 weeks with patients who continued antihistamines alone. Disease activity was measured with the weekly Urticaria Activity Score (UAS7), quality of life with the Dermatology Life Quality Index (DLQI), and adverse effects were recorded at every visit.

Read the detailed description

Chronic urticaria is a mast cell-driven skin disease with recurrent wheals, angioedema or both for more than 6 weeks. Many patients remain symptomatic on up-dosed second-generation H1 antihistamines, and second- and third-line options (omalizumab, cyclosporine) are costly or need laboratory monitoring. Apremilast is an oral phosphodiesterase-4 inhibitor approved for psoriasis, psoriatic arthritis and Behcet disease; PDE4 is expressed in mast cells, basophils and eosinophils.

Design: single-centre, open-label, non-randomised, parallel-group controlled trial at the Department of Dermatology, Arif Memorial Teaching Hospital, Rashid Latif Medical College, Lahore, Pakistan. Eighty-six patients were enrolled by non-probability consecutive sampling (43 per group). Sample size was calculated with 95% confidence and 80% power using an expected response of 76.92% with add-on therapy versus 48.08% with antihistamines alone.

Allocation: after counselling on cost, off-label use and expected adverse effects, patients who agreed to take apremilast formed the experimental group; the others formed the control group.

Intervention: apremilast titrated over 5 days from 10 mg to 30 mg twice daily and continued for 12 weeks, in addition to the patient's second-generation H1 antihistamine. Controls continued the antihistamine alone.

Assessments: UAS7 at baseline and weeks 2, 4, 8 and 12; DLQI and body weight at baseline and week 12; adverse effects, compliance and antihistamine requirement at each visit. Data were analysed in SPSS version 26 with the independent and paired t-tests and the chi-square or Fisher's exact test; p of 0.05 or less was considered significant.

02

Conditions studied

  • Chronic Urticaria
  • Chronic Spontaneous Urticaria
  • Chronic Inducible Urticaria

Browse trials for

Keywords

  • apremilast
  • phosphodiesterase 4 inhibitor
  • antihistamine
  • urticaria activity score
  • dermatology life quality index
03

In context

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

This study's planned enrollment of 86 is close to the median of 80 across 149 interventional studies indexed under Chronic Urticaria.

Browse Chronic Urticaria studies →

Lead sponsor

Rashid Latif Medical College is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years of either gender.
  • Chronic spontaneous urticaria, chronic inducible urticaria or both, lasting more than 6 weeks.
  • Moderate to severe disease (weekly Urticaria Activity Score, UAS7, of 16 or more) despite at least 4 weeks of second-generation H1 antihistamines at standard or up-dosed (up to fourfold) dose.
  • Inadequate response to, intolerance of, to or inability to access omalizumab or cyclosporine.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, planned pregnancy or lactation.
  • Uncontrolled depression or other uncontrolled psychiatric illness.
  • Urticarial vasculitis.
  • Use of omalizumab or cyclosporine within the previous 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Apremilast plus antihistamine

    Apremilast titrated over 5 days from 10 mg to 30 mg orally twice daily and continued for 12 weeks, in addition to the patient's second-generation H1 antihistamine at standard or up to fourfold dose.

    Drug: Apremilast · Drug: Second-generation H1 antihistamine

  • Active comparator
    Antihistamine alone

    Second-generation H1 antihistamine at standard or up to fourfold dose for 12 weeks without apremilast.

    Drug: Second-generation H1 antihistamine

Interventions

  • Oral apremilast, 5-day titration (10 mg to 30 mg) then 30 mg twice daily for 12 weeks.

    Also known as: Otezla

  • DrugSecond-generation H1 antihistamine

    Oral second-generation H1 antihistamine at the licensed dose or up-dosed up to fourfold, continued throughout the 12-week study.

06

What researchers measure

Primary outcomes

  1. Change in weekly Urticaria Activity Score (UAS7) from baseline to week 12

    UAS7 is the sum of daily wheal (0-3) and itch (0-3) scores over 7 days, range 0-42; higher scores mean more active disease. Change is compared between groups.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Dermatology Life Quality Index (DLQI) from baseline to week 12

    DLQI is a 10-item questionnaire scored 0-30; higher scores mean greater impairment of quality of life.

    Time frame: Baseline and 12 weeks

  2. Proportion of patients with at least 50% reduction in UAS7

    Treatment response defined as a fall of 50% or more from baseline UAS7.

    Time frame: 12 weeks

  3. Proportion of patients with well-controlled disease (UAS7 of 6 or less)

    UAS7 of 0 to 6 at week 12.

    Time frame: 12 weeks

  4. UAS7 at follow-up visits

    Mean UAS7 at each follow-up visit compared between groups.

    Time frame: Weeks 2, 4, 8 and 12

  5. Antihistamine requirement

    Antihistamine dose at week 12 recorded as reduced, unchanged or increased compared with baseline.

    Time frame: 12 weeks

  6. Number of participants with adverse effects

    Nausea, vomiting, diarrhoea, headache, abdominal discomfort, weight loss (3% or more of baseline weight), mood changes and other events recorded at each visit.

    Time frame: Up to 12 weeks

07

Study locations

1 site
  • Arif Memorial Teaching Hospital, Rashid Latif Medical College
    Lahore, Punjab Province, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2026, 1 month after the start.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartActual
Sep 23, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850843
Lead sponsor
Rashid Latif Medical College
Responsible party
Merrium Mahrukh (Postgraduate Resident, Department of Dermatology, Rashid Latif Medical College) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 23, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Sep 30, 2026

Study contacts

Merrium Mahrukh, MBBS
principal investigator · Rashid Latif Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion